Akebia Therapeutics (AKBA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/10/20
Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult PatientsPRNewsWire • 06/29/20
Akebia Therapeutics (AKBA) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 06/12/20
Akebia Therapeutics Announces Data on Different Dosing Regimens of Ferric Citrate for Iron Deficiency Anemia Presented at 57th ERA-EDTA Virtual CongressPRNewsWire • 06/10/20
Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional SharesPRNewsWire • 05/19/20
Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue?Zacks Investment Research • 05/13/20
How Akebia Therapeutics (AKBA) Stock Stands Out in a Strong IndustryZacks Investment Research • 05/11/20
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/05/20
Akebia's shares jump on late-stage clinical trial results for kidney disease drugMarket Watch • 05/05/20
Is the Options Market Predicting a Spike in Akebia Therapeutics (AKBA) Stock?Zacks Investment Research • 04/02/20
Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/10/20
Akebia Therapeutics (AKBA) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/10/20
Will Akebia Therapeutics (AKBA) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research • 03/03/20
Options Traders Expect Huge Moves in Akebia Therapeutics (AKBA) StockZacks Investment Research • 12/02/19